EUCTR2006-004945-40-FR进行中（未招募）1 期
A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in Combination with Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer Patients - Zalutumumab in Combination with Chemo-Radiation in NSCLC
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Genmab A/S
- 入组人数
- 270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histological or cytological diagnosis of NSCLC in one of the following subtypes: Squamous cell carcinoma, basaloid carcinoma, adenocarcinoma, adenosquamous carcinoma, large cell carcinoma, large cell neuroendocrine carcinoma, giant cell carcinoma, sarcomatoid carcinoma and non small cell carcinoma NOS
- •2. Any stage III NSCLC based on CT scan, due to invasion or involvement of mediastinal structures or lymph nodes. In the latter case, proof of nodal status involvement should be confirmed either by cytology or histology, or by appropriate PET imaging (for definition of nodal status, see section 20.2, Definition of Terms)
- •3. Performance status 0 or 1 (Zubrod or WHO Scale)
- •4. Age = 18 years
- •5. Following receipt of verbal and written information about the trial, the patient has provided signed informed consent before any trial related activity is carried out
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Evidence of metastases (based on whole body PET scan and CT scan or MRI of brain), either in a separate lobe of the lung, or extra thoracic
- •2. Pleural effusion
- •3. Patients in whom the necessary radiation treatment volume would result in a high risk of radiation pneumonitis (defined subsequently as V20 > 35%)
- •4. Estimated life expectancy of less than 3 months
- •5. Unwillingness and inability to attend the required follow-up
- •6. Bone marrow reserve: white blood cell count (WBC) < 3.0 x 10^9/L, neutrophils < 1.5 x 10^9/L, platelets < 100 x 10^9/L, hemoglobin < 10 g/dL
- •7. Renal function: creatinine clearance calculated by the Cockcroft and Gault equation < 50
- •8. Liver function: bilirubin > 1.5 x normal. ALT, alkaline phosphatase and AST > 2.5 x normal
- •9. Impaired respiratory function as indicated by a forced expiratory volume in 1 second (FEV1) of less than, or equal to, 40% of predicted normal values OR a diffusion capacity for carbon monoxide (DLCO) of less than, or equal to, 50% of predicted normal values (based on measurement of both parameters)
- •10. Evidence of malignancy in the past 2 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other in situ cancers
- •11. History of interstitial pneumonitis
- •12. Severe COPD requiring = 3 hospitalizations over the past year
- •13. Peripheral neuropathy > grade 1
- •14. Unwilling loss of weight = 15% in the 3 months prior to enrolment
- •15. Chronic or current infectious disease such as, but not limited to, chronic renal infection, sinusitis, tuberculosis, and chronic chest infection with bronchiectasis
- •16. Severe ongoing infection requiring intravenous antibiotic or antifungal therapy
- •17. Serious concomitant systemic disorder incompatible with the trial
- •18. Known HIV positive
- •19. Known hepatitis B or hepatitis C
- •20. Prior chemotherapy for lung cancer
- •21. Prior radiotherapy to the chest
- •22. Prior surgery with curative intent for lung cancer
- •23. Previous exposure to EGFr monoclonal antibodies and/or small molecule inhibitors of EGFr
- •24. Use of any anti-cancer or investigational agent in the 4 weeks immediately prior to screening
- •25. Current participation in any other interventional clinical trial
- •26. Breast feeding women or women with a positive pregnancy test at Visit 1
- •27. Male not willing to use adequate contraception during and for 12 months after last dose of zalutumumab or woman of childbearing potential not willing to use adequate contraception such as hormonal birth control or intrauterine device, during trial and 12 months after last dose of zalutumumab. For patients in the USA the use of a double barrier method is also considered adequate.
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in Combination with Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer Patients - Zalutumumab in Combination with Chemo-Radiation in NSCLCStage IIIA-IIIB Non Small Cell Lung CancerMedDRA version: 8.1Level: LLTClassification code 10029519Term: Non-small cell lung cancer stage IIIEUCTR2006-004945-40-CZGenmab A/S273
进行中（未招募）
不适用
A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in Combination with Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer Patients - Zalutumumab in Combination with Chemo-Radiation in NSCLCStage IIIA-IIIB Non Small Cell Lung CancerMedDRA version: 8.1Level: LLTClassification code 10029519Term: Non-small cell lung cancer stage IIIEUCTR2006-004945-40-HUGenmab A/S273
进行中（未招募）
不适用
A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in Combination with Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer Patients - Zalutumumab in Combination with Chemo-Radiation in NSCLCEUCTR2006-004945-40-DEGenmab A/S276
进行中（未招募）
1 期
A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in Combination with Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer Patients - Zalutumumab in Combination with Chemo-Radiation in NSCLCStage IIIA-IIIB Non Small Cell Lung CancerMedDRA version: 8.1Level: LLTClassification code 10029519Term: Non-small cell lung cancer stage IIIEUCTR2006-004945-40-BEGenmab A/S276
进行中（未招募）
1 期
A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in Combination with Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer Patients - Zalutumumab in Combination with Chemo-Radiation in NSCLCEUCTR2006-004945-40-GBGenmab A/S276